Pfizer, Inc. (NYSE:PFE) EVP Frank A. Damelio sold 94,409 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $3,209,906.00. Following the completion of the transaction, the executive vice president now directly owns 337,389 shares of the company’s stock, valued at approximately $11,471,226. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Pfizer, Inc. (PFE) opened at 35.36 on Friday. The company’s 50-day moving average is $33.64 and its 200-day moving average is $33.53. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.84. The firm has a market cap of $210.30 billion, a P/E ratio of 25.87 and a beta of 1.00.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. Pfizer’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the company earned $0.64 EPS. Equities research analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.62%. The ex-dividend date was Wednesday, August 2nd. Pfizer’s dividend payout ratio is currently 94.12%.
TRADEMARK VIOLATION WARNING: “Frank A. Damelio Sells 94,409 Shares of Pfizer, Inc. (PFE) Stock” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2017/09/17/pfizer-inc-pfe-evp-frank-a-damelio-sells-94409-shares-of-stock.html.
A number of analysts have weighed in on the stock. BMO Capital Markets reissued a “buy” rating and set a $37.00 price objective on shares of Pfizer in a report on Thursday. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective on the stock. in a report on Wednesday. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Thursday, August 24th. Berenberg Bank reaffirmed a “hold” rating and issued a $36.00 target price (down from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Finally, Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $37.72.
Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Pfizer by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after buying an additional 389,629 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Pfizer by 4.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after buying an additional 2,028,313 shares during the period. Fisher Asset Management LLC grew its stake in shares of Pfizer by 3.9% in the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock valued at $1,143,248,000 after buying an additional 1,275,832 shares during the period. Finally, LSV Asset Management grew its stake in shares of Pfizer by 0.6% in the 2nd quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock valued at $1,117,726,000 after buying an additional 199,100 shares during the period. 69.09% of the stock is owned by institutional investors and hedge funds.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.